Complete Announced during: Premarket · announced Tue 7:04a ET (premarket); before = Mon close; first trade Tue 7:05a ET; time = SEC 8-K acceptance
Altimmune (Nasdaq: ALT) reported topline results from a Phase 2 trial of pemvidutide in alcohol use disorder on July 28, 2026. The company said the trial met its primary endpoint. ClinicalTrials.gov lists 100 enrolled participants (NCT06987513).
Trial details
- Drug
- PemvidutideType Drug
- Treats
- Studied as a treatment for alcohol use disorder.Condition Alcohol Use Disorder (AUD)
- Patients
- 100 patients (actual enrollment)2 arms · 12 sites in 1 country
- Phase
- Phase 2
- Design
- Randomized, quadruple-blind, placebo-controlled, parallel-group
- Primary endpoint
- Change from baseline in the average number of heavy drinking days per week (Baseline to Weeks 21-24)
- Key secondary endpoints
- Proportion of subjects achieving a 2-level reduction in WHO risk drinking level
- Absolute change from baseline in average phosphatidylethanol (PEth) levels at Week 24
- Change from baseline in average number of drinks per drinking day
- Result
- Met endpointThe trial met its primary endpoint with a highly statistically significant reduction in heavy drinking days (HDD) versus placebo, with consistent positive results across important secondary endpoints, including the World Health Organization (WHO) Risk Drinking Levels (RDL), zero HDD and phosphatidyl ethanol (PEth) levels.
- Safety
- Given the known detrimental effects of alcohol on the liver, the liver-directed impact of glucagon in pemvidutide may provide further benefit in the treatment of AUD over GLP-1 alone, underscoring pemvidutide’s promising potential differentiation.” Efficacy Data Endpoint Placebo Pemvidutide…
- Sponsor
- Altimmune Nasdaq: ALT
- Dates
- Study start May 15, 2025Primary completion Jul 30, 2026Announced Jul 28, 2026, 7:04 AM ET (SEC 8-K filing time)
- Trial ID
- NCT06987513 ClinicalTrials.gov
About this trial
This randomized, quadruple-blind, placebo-controlled, parallel-group Phase 2 trial (NCT06987513) tested Pemvidutide in Alcohol Use Disorder (AUD). Studied as a treatment for alcohol use disorder. It enrolled 100 patients across 2 arms at 12 sites in 1 country. The primary endpoint was Change from baseline in the average number of heavy drinking days per week (Baseline to Weeks 21-24). Altimmune reported that the trial met its primary endpoint. The study started on May 15, 2025 and reached primary completion on Jul 30, 2026.
Sources
- Source: SEC EDGAR 8-K (EX-99.1)
- ClinicalTrials.gov record: NCT06987513
For information only. Not investment or medical advice. Prices are historical, from consolidated market data, and may contain errors. Always check the original source.